No Data
No Data
Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump
Grand Pharmaceutical Group (HKG:0512) recorded a 10% decline in attributable profit for the year ended Dec. 31, 2023, to HK$1.88 billion from HK$2.08 billion during the year-ago period, according to t
遠大醫藥:2023年年報
Changes in Hong Kong stocks | Yuanda Pharmaceutical (00512.HK) rose more than 6% in the intraday period, domestic carbon-14 isotopes to supply domestic nuclear drugs to the market at the end of the year ushered in new opportunities
Yuanda Pharmaceutical (00512.HK) rose more than 6% in the intraday period. As of press release, it rose 4.94% to HK$4.25, with a turnover of HK$21.15,900.
Hong Kong Stock Concept Tracking | China's first mass production of carbon-14 isotope domestically produced nuclear drugs ushered in new opportunities (with concept stocks)
At 13:48 on April 20, after two years of core irradiation, the first carbon-14 target was successfully removed from the Qinshan Nuclear Power Heavy Water Reactor Unit of China Nuclear Power Investment Holdings under the China Nuclear Power Group. This was the first time that China mass-produced carbon-14 isotopes, solving the problem that domestic carbon-14 isotopes are dependent on imports, and fully localizing carbon-14 supply. Carbon-14 is a radioactive isotope of carbon and is widely used as a tracer. Helicobacter pylori testing is its most representative use. In addition, fields such as pharmacokinetic research and beta-ray environmental monitoring systems also require carbon-14. Previously
Yuanda Pharmaceutical (00512.HK) received 95,000 additional shares from Chairman Tang Weikun
Gelonghui, April 22丨According to the latest equity disclosure data of the Stock Exchange, on April 19, 2024, Yuanda Pharmaceutical (00512.HK) was granted an increase of 95,000 shares at an average price of HK$3.91 per share on the market, involving approximately HK$371,500. After the increase in holdings, Tang Weikun's latest shareholding was 415,000 shares.
Yuanda Pharmaceutical (00512.HK) was granted an increase of 95,000 shares of common shares by Tang Weikun, worth approximately HK$371,500
On April 19, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 19, Tang Weikun increased his common share holdings of $Yuanda Pharmaceutical (00512.HK) by $95,000 at an average price of HK$3.91 per share on April 19, worth about HK$371,500. After the increase in holdings, Tang Weikun's latest shareholding was 415,000 shares, and the good position ratio was 0.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top executives of listed companies
No Data